Does Long-Term Survival in Patients With Pancreatic Cancer Really Exist?-Results From the CONKO-001 Study
Does Long-Term Survival in Patients With Pancreatic Cancer Really Exist?-Results From the CONKO-001 Study
复制标题
DOI：
10.1002/jso.23409
复制
发表时间：
2013-11-01
影响因子：
2.5
通讯作者：
Oettle, Helmut
中科院分区：
文献类型：
--
作者：
Sinn, Marianne;Striefler, Jana K.;Oettle, Helmut
胰腺癌患者的长期生存（LTS）仍然不常见，很少有数据可以确定长期幸存者。CONKO-001研究确定了吉西他滨在切除后作为辅助治疗，可能为回答这个问题提供数据。方法将conko -001总生存期为5年的患者与生存期患者进行比较
BackgroundLong-term survival (LTS) in patients (pts) with pancreatic cancer is still uncommon, little data is available to identify long-term survivors. The CONKO-001 study, which established gemcitabine after resection as adjuvant therapy, may provide data to answer this question.MethodsCONKO-001 pts with an overall survival 5 years were compared to those who survived